Diagnexia UK has launched its expanded accession facility at Exeter Science Park, where it is set to create 30 jobs.
The expansion is designed to bolster the company’s capacity to provide rapid, accurate and high-quality pathology services to multiple NHS trusts across the UK and at its operations in Toronto and Chicago.
Dr Donal O’Shea, chief executive of Diagnexia UK, said: “We are delighted to expand our presence in Exeter, a city that has consistently demonstrated its commitment to innovation and growth in the healthcare sector.
“Our new facility at Exeter Science Park will enable us to better serve our clients across the UK and beyond, while also providing valuable employment opportunities in the local community.”
The Deciphex Exeter Accession Facility is the central hub for the digitisation and upload of all biopsies to the Diagnexia platform. The expansion of the Exeter accession facility, along with the creation of 30 jobs this year, will triple capacity.
Sally Basker, chief executive of Exeter Science Park, added: “We are very pleased that Diagnexia has chosen to join our emerging health and life sciences cluster at Exeter Science Park.
“We help innovative science-based companies to deliver extraordinary growth and so we are excited to see 450 per cent growth opportunities opening up for Diagnexia with the promise of high value jobs, enhanced productivity and economic growth.”
The expansion has been supported by the South West Local Enterprise Partnership through the award of the European Regional Development Fund Inward Investment Support Grant Scheme to Deciphex.
